Canakinumab for the treatment of active systemic juvenile idiopathic arthritis

Janet E. Orrock, Norman Todd Ilowite

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications. Areas covered: This article provides an overview of chemistry of canakinumab as well as the phase II and phase III trials that led to approval for treatment of active SJIA. To undertake this review, the authors performed literature search using Pubmed, with keywords ‘canakinumab,’ ‘biologic,’ ‘anti-IL-1B,’ and ‘systemic juvenile idiopathic arthritis,’ focusing on publications within the last 5 years. Expert commentary: Canakinumab has shown efficacy in treatment of SJIA with active systemic features including fever. There is no evidence to suggest increased risk of macrophage activation syndrome. Its use in the treatment of chronic arthritis without active systemic features has not been approved and warrants further study.

Original languageEnglish (US)
Pages (from-to)1015-1024
Number of pages10
JournalExpert Review of Clinical Pharmacology
Volume9
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Juvenile Arthritis
Macrophage Activation Syndrome
Therapeutics
Interleukin-1
PubMed
Arthritis
Publications
Fever
Monoclonal Antibodies
canakinumab

Keywords

  • anti-IL-1β
  • biologic
  • canakinumab
  • mAb
  • monoclonal antibody
  • SJIA
  • systemic JIA
  • Systemic juvenile idiopathic arthritis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. / Orrock, Janet E.; Ilowite, Norman Todd.

In: Expert Review of Clinical Pharmacology, Vol. 9, No. 8, 02.08.2016, p. 1015-1024.

Research output: Contribution to journalArticle

@article{c9df50d7c5994b5ab95df7541dd8c1db,
title = "Canakinumab for the treatment of active systemic juvenile idiopathic arthritis",
abstract = "Introduction: Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications. Areas covered: This article provides an overview of chemistry of canakinumab as well as the phase II and phase III trials that led to approval for treatment of active SJIA. To undertake this review, the authors performed literature search using Pubmed, with keywords ‘canakinumab,’ ‘biologic,’ ‘anti-IL-1B,’ and ‘systemic juvenile idiopathic arthritis,’ focusing on publications within the last 5 years. Expert commentary: Canakinumab has shown efficacy in treatment of SJIA with active systemic features including fever. There is no evidence to suggest increased risk of macrophage activation syndrome. Its use in the treatment of chronic arthritis without active systemic features has not been approved and warrants further study.",
keywords = "anti-IL-1β, biologic, canakinumab, mAb, monoclonal antibody, SJIA, systemic JIA, Systemic juvenile idiopathic arthritis",
author = "Orrock, {Janet E.} and Ilowite, {Norman Todd}",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/17512433.2016.1204910",
language = "English (US)",
volume = "9",
pages = "1015--1024",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Canakinumab for the treatment of active systemic juvenile idiopathic arthritis

AU - Orrock, Janet E.

AU - Ilowite, Norman Todd

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Introduction: Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications. Areas covered: This article provides an overview of chemistry of canakinumab as well as the phase II and phase III trials that led to approval for treatment of active SJIA. To undertake this review, the authors performed literature search using Pubmed, with keywords ‘canakinumab,’ ‘biologic,’ ‘anti-IL-1B,’ and ‘systemic juvenile idiopathic arthritis,’ focusing on publications within the last 5 years. Expert commentary: Canakinumab has shown efficacy in treatment of SJIA with active systemic features including fever. There is no evidence to suggest increased risk of macrophage activation syndrome. Its use in the treatment of chronic arthritis without active systemic features has not been approved and warrants further study.

AB - Introduction: Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications. Areas covered: This article provides an overview of chemistry of canakinumab as well as the phase II and phase III trials that led to approval for treatment of active SJIA. To undertake this review, the authors performed literature search using Pubmed, with keywords ‘canakinumab,’ ‘biologic,’ ‘anti-IL-1B,’ and ‘systemic juvenile idiopathic arthritis,’ focusing on publications within the last 5 years. Expert commentary: Canakinumab has shown efficacy in treatment of SJIA with active systemic features including fever. There is no evidence to suggest increased risk of macrophage activation syndrome. Its use in the treatment of chronic arthritis without active systemic features has not been approved and warrants further study.

KW - anti-IL-1β

KW - biologic

KW - canakinumab

KW - mAb

KW - monoclonal antibody

KW - SJIA

KW - systemic JIA

KW - Systemic juvenile idiopathic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84978971986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978971986&partnerID=8YFLogxK

U2 - 10.1080/17512433.2016.1204910

DO - 10.1080/17512433.2016.1204910

M3 - Article

VL - 9

SP - 1015

EP - 1024

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 8

ER -